Reata Pharmaceuticals Inc - Ordinary Shares - Class A

NASDAQ:RETA  
28.79
+1.11 (+4.01%)
Earnings Announcements

Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results And Provides An Update On Clinical Development Programs

Published: 05/10/2022 10:48 GMT
Reata Pharmaceuticals Inc - Ordinary Shares - Class A (RETA) - Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs.
Q1 Non-GAAP Loss per Share $1.33.
Q1 GAAP Loss per Share $2.03.
Reaffirms Cash Runway Through End of 2024.
Updates Outcome of Type a Meeting With FDA on Protocol Amendment for Falcon.
Reata Pharma - Falcon is Enrolling Patients in a Broad Range of Ages With an Estimated Glomerular Filtration Rate Between 30 and 90 Ml/min/1.73 M.
Division Stated That Proposed Primary Endpoint of Egfr Change From Baseline at Week 108 Was Reasonable.
FDA Also Confirmed That, If Falcon Trial is Positive, It Could Support Registration of Bardoxolone in Adpkd.
Revenue is expected to be $1.46 Million
Adjusted EPS is expected to be -$2.10

Next Quarter Revenue Guidance is expected to be $1.31 Million
Next Quarter EPS Guidance is expected to be -$2.22

More details on our Analysts Page.